Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Digital health

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    161 result(s) found for: Digital health. Displaying page 1 of 9.
    1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2014-002796-28 Sponsor Protocol Number: CEASESTIFFNESS Start Date*: 2016-04-12
    Sponsor Name:University Medical Center Groningen (UMCG)
    Full Title: The Clinical Efficacy And Subclinical Effects on arterial STIFFNESS of bosentan therapy added to usual care in patients with systemic sclerosis with digital ulcers.
    Medical condition: Systemic sclerosis (SSc) is characterized by skin fibrosis and visceral disease, mainly of the lungs, kidneys and the heart, accompanied by microvascular damage ultimately leading to digital ischem...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002288-29 Sponsor Protocol Number: IEOS626/311 Start Date*: 2012-03-29
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: New frontiers in breast imaging: contrast enhanced digital mammography. - Clinical performance of contrast-enhanced spectral mammography (CESM - SenoBright) in pre-surgical evaluation of extent o...
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10012992 Digital mammography LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022710-77 Sponsor Protocol Number: AC-055C301 Start Date*: 2011-06-16
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: Prospective, randomized, placebo-controlled, double-blind, multicenter, parallel group study to assess the efficacy, safety and tolerability of macitentan in patients with ischemic digital ulcers a...
    Medical condition: Ischemic digital ulcers associated with systemic sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10042953 Systemic sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) CZ (Completed) DK (Prematurely Ended) BG (Completed) FI (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-009598-90 Sponsor Protocol Number: 91782 Start Date*: 2010-08-20
    Sponsor Name:Bayer Health Care AG (study performed by Bayer Schering Pharma AG)
    Full Title: An open label, multi-center, phase 3 study with corresponding blinded image reading to determine the efficacy and safety of a single intravenous injection of 0.1 mmol/kg body weight of gadobutrol 1...
    Medical condition: Patients with histologically confirmed breast cancer referred to MRM prior to surgery after XRM.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012992 Digital mammography LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-009597-27 Sponsor Protocol Number: BAY86-4875/91743 Start Date*: Information not available in EudraCT
    Sponsor Name:Bayer Health Care AG (study performed by Bayer Schering Pharma AG)
    Full Title: An open label, multi-center, phase 3 study with corresponding blinded image reading to determine the efficacy and safety of a single intravenous injection of 0.1 mmol/kg body weight of gadobutrol 1...
    Medical condition: Patients with histologically confirmed breast cancer referred to MRM prior to surgery after XRM.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10012992 Digital mammography LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022969-95 Sponsor Protocol Number: AC-055C302 Start Date*: 2011-12-21
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: Prospective, randomized, placebo-controlled, double-blind, multicenter, parallel group study to assess the efficacy, safety and tolerability of macitentan in patients with ischemic digital ulcers a...
    Medical condition: Ischemic digital ulcers associated with systemic sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10042953 Systemic sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) IE (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended) NL (Completed) PT (Prematurely Ended) PL (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000905-24 Sponsor Protocol Number: 25052004 Start Date*: 2005-02-08
    Sponsor Name:University of York
    Full Title: Cryotherapy versus salicylic acid for the treatment of verrucae: a randomised controlled trial.
    Medical condition: Verrucae
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2008-005018-39 Sponsor Protocol Number: TDE-DU-201 Start Date*: 2009-03-05
    Sponsor Name:United Therapeutics Corporation
    Full Title: DISTOL-1:Digital Ischaemic Lesions in Scleroderma treated with Oral Treprostinil Diethanolamine: A randomized, double-blind, placebo controlled, multicenter study
    Medical condition: Systemic Sclerosis, scleroderma digital ulcers
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042953 Systemic sclerosis LLT
    9.1 10039710 Scleroderma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-004169-42 Sponsor Protocol Number: 20393 Start Date*: 2020-08-20
    Sponsor Name:Bayer AG
    Full Title: Randomized, double-blind, parallel group, Phase 2b dose-finding, efficacy and safety study of 12-week twice daily oral administration of BAY 1817080 compared to placebo in the treatment of refracto...
    Medical condition: Refractory and/or unexplained chronic cough (RUCC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004855 10080782 Refractory chronic cough LLT
    21.0 100000004855 10080781 Unexplained chronic cough LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) IT (Completed) NL (Completed) CZ (Completed) HU (Completed) SK (Completed) BE (Completed) PL (Completed) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005303-32 Sponsor Protocol Number: AC-052-438 Start Date*: 2012-03-05
    Sponsor Name:Actelion Pharmaceuticals Nederland bv
    Full Title: Effects of bosentan in a HOMogenEous population of SSc subjects with an early or active SSc nailfold capillaroscopic pattern (HOME II)
    Medical condition: Digital Ulcera in Systemic Sclerodermia patients
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10053400 Endothelin increased PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2004-000632-82 Sponsor Protocol Number: AC-052-333 Start Date*: 2004-09-16
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: Long term bosentan open label extension of the RAPIDS-2 study in Systemic Sclerosis patients with ischemic digital ulcers
    Medical condition: SSc is a multi-system disorder of unknown etiology characterized by fibrosis and vascular obliteration in the skin and visceral organs. The pathogenesis of SSc involves immunologic mechanisms vascu...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-002494-10 Sponsor Protocol Number: Start Date*: 2020-07-17
    Sponsor Name:Queen Mary University of London
    Full Title: Personalised Electronic Record Supported OptimisatioN when ALone for Patients with Hypertension- Pilot Study for Remote Medical Management of Hypertension During the COVID-19 Pandemic
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10081425 Arterial hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2021-003951-41 Sponsor Protocol Number: BFS-AS-40184 Start Date*: 2023-05-04
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: CONNected Electronic Inhalers Asthma Control Trial 3 (“CONNECT 3”), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison Study of Standard of Care Treatment Versus th...
    Medical condition: Asthma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000380-27 Sponsor Protocol Number: 192024-058Amendment3 Start Date*: 2011-06-21
    Sponsor Name:Allergan Ltd.
    Full Title: A Multicenter, Randomized, Double-blind, Parallel-group Study to Evaluate the Safety and Efficacy of Bimatoprost Solution 0.03%, 0.1%, and 0.3% Compared with Vehicle in Women with Female Pattern Ha...
    Medical condition: Female pattern hair loss
    Disease: Version SOC Term Classification Code Term Level
    14.0 10040785 - Skin and subcutaneous tissue disorders 10016407 Female pattern hair thinning LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000379-15 Sponsor Protocol Number: 192024-057 Amendment 2 Start Date*: 2011-06-21
    Sponsor Name:Allergan Ltd.
    Full Title: A Multicenter, Randomized, Double-blind, Parallel-group Study to Evaluate the Safety and Efficacy of Bimatoprost Solution 0.03%, 0.1%, and 0.3% Compared with Vehicle in Men with Androgenic Alopecia...
    Medical condition: Androgenic alopecia in men
    Disease: Version SOC Term Classification Code Term Level
    14.0 10040785 - Skin and subcutaneous tissue disorders 10068558 Androgenic alopecia LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003249-34 Sponsor Protocol Number: F13640GE209 Start Date*: 2007-09-24
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: Proof of Concept study of the efficacy and tolerability of a 4-week treatment with F13640 in patients in whom the adaptation of opioid therapy of cancer pain has failed. A prospective, multinationa...
    Medical condition: Patients who have failed adaptation of opioid therapy for cancer pain
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058019 Cancer pain LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) BE (Completed) CZ (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004979-37 Sponsor Protocol Number: 06-004 Start Date*: 2006-10-27
    Sponsor Name:MediQuest Therapeutics, Inc.
    Full Title: Phase III “In-Life” Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud’s Phenomenon
    Medical condition: Moderate to severe primary Raynaud’s, OR patients with Raynaud’s phenomenon secondary to autoimmune diseases, such as scleroderma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002209-22 Sponsor Protocol Number: 7197 Start Date*: 2005-09-23
    Sponsor Name:University Hospitals of Leicester NHS Trust
    Full Title: A randomised, placebo-controlled, rising-dose crossover study to evaluate the effectiveness of modafinil in the management of fatigue in fibromyalgia
    Medical condition: Fibromyalgia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-000531-17 Sponsor Protocol Number: D5160C00002 Start Date*: 2014-05-20
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of AZD9291 in Patients with EGFRm+/T790M+, Locally Advanced or Metastatic NSCLC who have Progressed Following Prior Therap...
    Medical condition: Non Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2021-001415-90 Sponsor Protocol Number: MO42720 Start Date*: 2022-12-12
    Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
    Full Title: INTERVENTIONAL PLATFORM STUDY INVESTIGATING THE IMPACT OF DIGITAL HEALTH SOLUTIONS ON HEALTH OUTCOMES AND HEALTH-CARE RESOURCE UTILIZATION IN PARTICIPANTS RECEIVING SYSTEMIC TREATMENT IN CLINICAL P...
    Medical condition: Cohort A: ●Metastatic non-small cell lung carcinoma (mNSCLC) ●Extensive-stage small-cell lung carcinoma (ES-SCLC) ●Advanced or unresectable hepatocellular carcinoma (HCC) Cohort B: Resected Stag...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10025064 Lung carcinoma LLT
    21.0 100000004864 10036706 Primary liver cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) AT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 14:19:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA